Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||PIK3CA E726K PIK3CA H1047R|
|Indication/Tumor Type||breast cancer|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA E726K PIK3CA H1047R||breast cancer||sensitive||Alpelisib||Preclinical - Cell culture||Actionable||In a preclinical study, breast epithelial cells expressing PIK3CA E726 and PIK3CA H1047R in cis demonstrated increased sensitivity to growth inhibition by Piqray (Alpelisib) treatment compared to cells expressing individual PIK3CA mutations in culture, while cells expressing PIK3CA E726 and PIK3CA H1047R in trans did not (PMID: 31699932).||31699932|
|PubMed Id||Reference Title||Details|
|(31699932)||Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.||Full reference...|